Eisai, Biogen Alzheimer's drug Leqembi would cost US Medicare up to $5 billion a year, study finds

Wide coverage of Alzheimer's drug Leqembi would raise future costs for the U.S. Medicare health plan by $2 billion to $5 billion a year, according to a study led by researchers at the University... | May 11, 2023

Related Keywords

United States ,Americans ,Deena Beasley ,Medicaid Services ,Biogen Inc ,Centers For Medicare ,Eisai Co Ltd ,Drug Administration ,Cave Arbanas ,John Mafi ,Reporting By Deena Beasley ,Bill Berkrot ,Biogen Inc Stock Exchange ,News ,Information ,Press Release ,Tide ,Coverage ,F ,Drug ,Leqembi ,Would ,Raise ,Future ,Costs ,Or ,The ,Medicare ,Health ,Plan ,Y ,Billion ,O ,Ccording ,Study ,Bed ,Researchers ,It ,He Biib Us09062x1037 ,